Zymeworks Inc. (NYSE:ZYME - Free Report) - Investment analysts at HC Wainwright lifted their Q2 2025 earnings estimates for Zymeworks in a research report issued to clients and investors on Tuesday, May 20th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.45) for the quarter, up from their prior estimate of ($0.47). HC Wainwright currently has a "Neutral" rating and a $13.00 price target on the stock. The consensus estimate for Zymeworks' current full-year earnings is ($1.39) per share. HC Wainwright also issued estimates for Zymeworks' Q3 2025 earnings at ($0.48) EPS, Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($1.75) EPS, Q1 2026 earnings at ($0.48) EPS, Q2 2026 earnings at ($0.49) EPS, Q3 2026 earnings at ($0.52) EPS, Q4 2026 earnings at ($0.55) EPS and FY2026 earnings at ($2.04) EPS.
Several other equities analysts have also weighed in on the stock. Lifesci Capital began coverage on shares of Zymeworks in a report on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 target price on the stock. Citigroup increased their price objective on shares of Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, March 7th. TD Securities initiated coverage on shares of Zymeworks in a research report on Tuesday, May 20th. They issued a "buy" rating on the stock. Finally, TD Cowen started coverage on shares of Zymeworks in a research note on Tuesday, May 20th. They set a "buy" rating for the company. Two investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $21.00.
Check Out Our Latest Research Report on Zymeworks
Zymeworks Trading Down 1.2%
ZYME traded down $0.14 during trading on Thursday, hitting $11.40. The company's stock had a trading volume of 71,204 shares, compared to its average volume of 598,528. The business's fifty day simple moving average is $11.73 and its 200 day simple moving average is $13.24. Zymeworks has a twelve month low of $8.21 and a twelve month high of $17.70. The firm has a market capitalization of $793.32 million, a price-to-earnings ratio of -7.62 and a beta of 1.24.
Zymeworks (NYSE:ZYME - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.45) by $0.15. Zymeworks had a negative return on equity of 23.00% and a negative net margin of 182.75%. The firm had revenue of $27.11 million during the quarter, compared to analyst estimates of $20.65 million. During the same quarter in the previous year, the business earned ($0.42) earnings per share. Zymeworks's quarterly revenue was up 170.3% on a year-over-year basis.
Insider Buying and Selling at Zymeworks
In other Zymeworks news, Director Ecor1 Capital, Llc purchased 320,690 shares of the business's stock in a transaction that occurred on Tuesday, March 11th. The stock was acquired at an average cost of $11.49 per share, with a total value of $3,684,728.10. Following the completion of the acquisition, the director now directly owns 16,040,851 shares of the company's stock, valued at $184,309,377.99. This represents a 2.04% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have purchased a total of 1,405,768 shares of company stock worth $16,773,032 over the last 90 days. Insiders own 1.92% of the company's stock.
Hedge Funds Weigh In On Zymeworks
Institutional investors have recently modified their holdings of the stock. Sterling Capital Management LLC raised its stake in Zymeworks by 781.5% in the 4th quarter. Sterling Capital Management LLC now owns 1,719 shares of the company's stock valued at $25,000 after acquiring an additional 1,524 shares during the period. CWM LLC raised its position in shares of Zymeworks by 1,091.2% during the first quarter. CWM LLC now owns 2,299 shares of the company's stock worth $27,000 after acquiring an additional 2,106 shares during the last quarter. AlphaQuest LLC raised its position in shares of Zymeworks by 480.2% during the fourth quarter. AlphaQuest LLC now owns 2,808 shares of the company's stock worth $41,000 after acquiring an additional 2,324 shares during the last quarter. GAMMA Investing LLC increased its holdings in Zymeworks by 1,113.3% in the first quarter. GAMMA Investing LLC now owns 6,467 shares of the company's stock worth $77,000 after purchasing an additional 5,934 shares in the last quarter. Finally, BNP Paribas Financial Markets bought a new stake in shares of Zymeworks during the fourth quarter valued at approximately $108,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.
Zymeworks Company Profile
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Featured Articles

Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.